Endometrial Adenocarcinoma Clinical Trial
Official title:
Evaluation of the Efficacy for Sentinel Lymph Node Policy in High-risk Endometrial Carcinoma
To evaluate the efficacy of sentinel lymph node biopsy technique in patients with high-risk endometrial carcinoma, which provides the evidence that sentinel lymph node biopsy technique could substitute the systematic Lymph node dissection(LND).
Comprehensive surgical staging for endometrial carcinoma(EC) is an indisputable staging and prognostic tool. The staging procedure includes total hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy, omental biopsy if necessary. Since lymph node metastasis is one of the most important risk factors of prognosis. The dissection of lymph nodes has been used for staging, prognostic information, and to determine the need for adjuvant therapy. The approach to lymph node evaluation in women with EC is still a subject of debate. Practice varies across different institutions or surgeons. In general, the options for management of retroperitoneal lymph nodes include no lymph node dissection (LND), systematic LND only if the risk of lymph node metastasis exceeds a certain threshold, or routine sentinel LND following lymphatic mapping. lymphadenectomy is significantly associated with longer operating time, higher surgical costs, greater rate of infection, as well as the occurrence of lymphocysts and lymphedema, moreover, there is lack of evidence of a therapeutic benefit of LND, less invasive techniques have emerged as possible alternatives. The technique for lymphatic mapping and sentinel lymph node dissection (SLND) in EC has been refined and found a low false-negative rate for detection of positive lymph nodes. The 2018 National Comprehensive cancer Network (NCCN) guideline of uterus cancer states SLN mapping can be considered for the surgical staging of apparent uterine-confined malignancy when there is no metastasis demonstrated by imaging studies or no obvious extrauterine disease at exploration. It indicates low-risk patients could avoid those side effects of the systematic Lymph node dissection. Whether high-risk patients (grade 3, deep myometrial invasion, non-endometrioid endometrial cancer, and Cervical invasion) can be benefited from this technique? This prospective cohort study is designed to To evaluate the efficacy of sentinel lymph node biopsy technique in patients with high-risk endometrial carcinoma. Surgery should be performed within a maximum of 4 weeks from the patient's first consultation. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01935973 -
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03660826 -
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
|
Phase 2 | |
Active, not recruiting |
NCT04106414 -
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
|
Phase 2 | |
Completed |
NCT01642082 -
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01208467 -
Prognostic Biomarkers in Patients With Endometrial Cancer
|
N/A | |
Completed |
NCT01011933 -
Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT00025467 -
Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01440998 -
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
|
Phase 1 | |
Completed |
NCT00006089 -
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00977574 -
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
Completed |
NCT01968317 -
Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
|
Phase 2 | |
Completed |
NCT01225887 -
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01005329 -
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02208375 -
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03836157 -
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06399757 -
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00095979 -
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT00072176 -
Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03460483 -
Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care
|
N/A |